FindTrial
Sign In

Comparing efficacy of continuous v/s intermittent doses of lasix using VExUS

Comparison of Continuous Versus Intermittent Doses of Furosemide Using VExUS Guided Decongestion in Critically Ill Patients with Moderate Chronic Renal Failure - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/06/088474
Enrollment
50
Registered
2025-06-10
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N183- Chronic kidney disease, stage 3 (moderate)

Interventions

Intervention1: Furosemide: Continuous IV infusion of Injection furosemide 10mg/hour for 24 hours versus Intermittent bolus doses of 60mg of Injection furosemide IV every 4 hours for 24 hours. Control

Sponsors

Aster CMI Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with chronic kidney dysfunction (eGFR upto 15ml/min/1.73m2)

Exclusion criteria

Exclusion criteria: Patients already undergoing renal replacement therapy Patients on invasive mechanical ventilation Patients allergic to furosemide Pregnant females

Design outcomes

Primary

MeasureTime frame
To compare continuous versus intermittent furosemide dosage in critically ill patients with moderate kidney dysfunction utilising Venous Excess UltraSound (VExUS) guided decongestion and total urinary volume at different time intervals at baseline, 6 hours, 12 hours, 18 hours and 24 hours.Timepoint: Baseline, 6 hours, 12 hours, 18 hours and 24 hours.—

Secondary

MeasureTime frame
Clinical symptoms, length of ICU stayTimepoint: Baseline, 6 hours, 12 hours, 18 hours and 24 hours.—

Countries

India

Contacts

Public ContactDr Shivangi Saxena

Aster CMI Hospital

drprakash.doraiswamy@asterhospital.in7259792468

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026